← Back to All US Stocks

GLAUKOS Corp (GKOS) Stock Fundamental Analysis & AI Rating 2026

GKOS NYSE Surgical & Medical Instruments & Apparatus DE CIK: 0001192448
Updated This Month • Analysis: May 6, 2026 • SEC Data: 2026-03-31
Combined AI Rating
HOLD
70% Confidence
STRONG AGREEMENT
HOLD
75% Conf
HOLD
64% Conf

📊 GKOS Key Takeaways

Revenue: $150.6M
Net Margin: -13.1%
Free Cash Flow: $-16.5M
Current Ratio: 5.43x
Debt/Equity: 0.00x
EPS: $-0.34
AI Rating: HOLD with 75% confidence
GLAUKOS Corp (GKOS) receives a HOLD rating with 70% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $150.6M, net profit margin of -13.1%, and return on equity (ROE) of -2.9%, GLAUKOS Corp demonstrates mixed fundamentals in the Healthcare sector. Below is our complete GKOS stock analysis for 2026.

Is GLAUKOS Corp (GKOS) a Good Investment?

Claude

GKOS demonstrates strong revenue growth (32.3% YoY) and exceptional gross margins (77.9%), indicating a fundamentally sound business model with pricing power. However, significant operational challenges persist with operating losses (-13.2% margin) and negative operating cash flow (-12.5M), suggesting the company is in a costly growth/investment phase. A strong balance sheet (104.2M cash, minimal debt) provides financial runway, but profitability and cash flow inflection points are critical for long-term viability.

ChatGPT

Glaukos shows robust revenue growth and solid gross margins, but continues to post sizable operating and net losses with negative free cash flow. A strong, low-leverage balance sheet reduces near‑term solvency risk, yet the path to operating leverage remains unproven. Maintain a HOLD pending clear progress toward positive operating cash flow and improving operating margins.

Why Buy GLAUKOS Corp Stock? GKOS Key Strengths

Claude
  • + Strong revenue growth of 32.3% YoY demonstrates market demand and successful commercialization
  • + Exceptional gross margin of 77.9% indicates strong pricing power, product quality, and sustainable business model
  • + Fortress balance sheet with 104.2M cash, minimal debt (3.0M), and excellent liquidity ratios (5.43x current ratio)
ChatGPT
  • + 32% YoY revenue growth indicating strong demand
  • + Healthy 55.7% gross margin supporting attractive unit economics
  • + Strong liquidity and minimal leverage (current ratio 4.69x, low debt)

GKOS Stock Risks: GLAUKOS Corp Investment Risks

Claude
  • ! Negative operating cash flow (-12.5M) and negative free cash flow (-16.5M) indicate operational cash burn despite revenue growth
  • ! Operating losses of -19.9M with -13.2% margin suggest SG&A and R&D expenses are misaligned with revenue trajectory
  • ! Unsustainable burn rate: at current -16.5M FCF, cash runway limited; path to profitability must be demonstrated soon
ChatGPT
  • ! Persistent operating losses and -39.3% operating margin
  • ! Negative operating and free cash flow may necessitate future capital needs
  • ! Execution risk in scaling while controlling R&D/SG&A to achieve operating leverage

Key Metrics to Watch

Claude
  • * Operating cash flow inflection point and timeline to positive OCF
  • * Operating margin expansion trajectory and cost structure optimization
  • * Cash burn rate sustainability and quarters of remaining runway
ChatGPT
  • * Operating cash flow trend toward positive
  • * Operating margin improvement (opex as % of revenue)

GLAUKOS Corp (GKOS) Financial Metrics & Key Ratios

Revenue
$150.6M
Net Income
$-19.8M
EPS (Diluted)
$-0.34
Free Cash Flow
$-16.5M
Total Assets
$893.3M
Cash Position
$104.2M

💡 AI Analyst Insight

Strong liquidity with a 5.43x current ratio provides a solid financial cushion.

GKOS Profit Margin, ROE & Profitability Analysis

Gross Margin 77.9%
Operating Margin -13.2%
Net Margin -13.1%
ROE -2.9%
ROA -2.2%
FCF Margin -10.9%

GKOS vs Healthcare Sector: How GLAUKOS Corp Compares

How GLAUKOS Corp compares to Healthcare sector averages

Net Margin
GKOS -13.1%
vs
Sector Avg 12.0%
GKOS Sector
ROE
GKOS -2.9%
vs
Sector Avg 15.0%
GKOS Sector
Current Ratio
GKOS 5.4x
vs
Sector Avg 2.0x
GKOS Sector
Debt/Equity
GKOS 0.0x
vs
Sector Avg 0.6x
GKOS Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is GLAUKOS Corp Stock Overvalued? GKOS Valuation Analysis 2026

Based on fundamental analysis, GLAUKOS Corp has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
-2.9%
Sector avg: 15%
Net Profit Margin
-13.1%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
0.00x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

GLAUKOS Corp Balance Sheet: GKOS Debt, Cash & Liquidity

Current Ratio
5.43x
Quick Ratio
4.73x
Debt/Equity
0.00x
Debt/Assets
24.9%
Interest Coverage
-5.76x
Long-term Debt
$3.0M

GKOS Revenue & Earnings Growth: 5-Year Financial Trend

GKOS 5-year financial data: Year 2021: Revenue $294.0M, Net Income $15.4M, EPS $0.37. Year 2022: Revenue $294.0M, Net Income -$120.3M, EPS $-2.70. Year 2023: Revenue $314.7M, Net Income -$49.6M, EPS $-1.07. Year 2024: Revenue $383.5M, Net Income -$99.2M, EPS $-2.09. Year 2025: Revenue $507.4M, Net Income -$134.7M, EPS $-2.78.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: GLAUKOS Corp's revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.78 indicates the company is currently unprofitable.

GKOS Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-10.9%
Free cash flow / Revenue

GKOS Quarterly Earnings & Performance

Quarterly financial performance data for GLAUKOS Corp including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q1 2026 $106.7M -$18.1M $-0.32
Q3 2025 $96.7M -$16.2M $-0.28
Q2 2025 $95.7M -$19.7M $-0.34
Q1 2025 $85.6M -$18.1M $-0.32
Q3 2024 $78.0M -$21.4M $-0.39
Q2 2024 $80.4M -$32.8M $-0.68
Q1 2024 $73.9M -$34.6M $-0.72
Q3 2023 $71.3M -$27.6M $-0.58

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

GLAUKOS Corp Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$12.5M
Cash generated from operations
Stock Buybacks
$132.0K
Shares repurchased (TTM)
Capital Expenditures
$4.0M
Investment in assets
Dividends
None
No dividend program

GKOS SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for GLAUKOS Corp (CIK: 0001192448)

📋 Recent SEC Filings

Date Form Document Action
May 18, 2026 4 xslF345X06/form4-05182026_110531.xml View →
May 13, 2026 4 xslF345X06/form4-05132026_110537.xml View →
May 4, 2026 4 xslF345X06/form4-05042026_100528.xml View →
May 4, 2026 4 xslF345X06/form4-05042026_100505.xml View →
May 4, 2026 4 xslF345X06/form4-05042026_100551.xml View →

Frequently Asked Questions about GKOS

What is the AI rating for GKOS?

GLAUKOS Corp (GKOS) has a Combined AI Rating of HOLD from Claude (HOLD) and ChatGPT (HOLD) with 70% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are GKOS's key strengths?

Claude: Strong revenue growth of 32.3% YoY demonstrates market demand and successful commercialization. Exceptional gross margin of 77.9% indicates strong pricing power, product quality, and sustainable business model. ChatGPT: 32% YoY revenue growth indicating strong demand. Healthy 55.7% gross margin supporting attractive unit economics.

What are the risks of investing in GKOS?

Claude: Negative operating cash flow (-12.5M) and negative free cash flow (-16.5M) indicate operational cash burn despite revenue growth. Operating losses of -19.9M with -13.2% margin suggest SG&A and R&D expenses are misaligned with revenue trajectory. ChatGPT: Persistent operating losses and -39.3% operating margin. Negative operating and free cash flow may necessitate future capital needs.

What is GKOS's revenue and growth?

GLAUKOS Corp reported revenue of $150.6M.

Does GKOS pay dividends?

GLAUKOS Corp does not currently pay dividends.

Where can I find GKOS SEC filings?

Official SEC filings for GLAUKOS Corp (CIK: 0001192448) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is GKOS's EPS?

GLAUKOS Corp has a diluted EPS of $-0.34.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is GKOS a good stock to buy right now?

Based on our AI fundamental analysis in May 2026, GLAUKOS Corp has a HOLD rating with 70% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is GKOS stock overvalued or undervalued?

Valuation metrics for GKOS: ROE of -2.9% (sector avg: 15%), net margin of -13.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy GKOS stock in 2026?

Our dual AI analysis gives GLAUKOS Corp a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is GKOS's free cash flow?

GLAUKOS Corp's operating cash flow is $-12.5M, with capital expenditures of $4.0M. FCF margin is -10.9%.

How does GKOS compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -13.1% (avg: 12%), ROE -2.9% (avg: 15%), current ratio 5.43 (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 6, 2026 | Data as of: 2026-03-31 | Powered by Claude AI